- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01332929
Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis
This phase I pilot study aims to define the safety of a combined treatment of bevacizumab and whole brain radiation therapy for the treatment of patients with brain metastasis of solid tumors. If this therapeutic scheme confirms it's safety profile, the investigators can expect:
- first, to allow that all patients can receive bevacizumab for their advanced and/or metastatic cancer if necessary, even in case of brain metastasis.
- Secondly, if this trial confirm a synergic effect of the combination of angiogenesis inhibitors and brain radiotherapy for local control of brain metastasis, an improvement of the therapeutic results for these patients which have a poor hope of survival and for which none innovative approach is currently suggested.
Moreover, the investigators hope that the analysis of the different data of MRI evaluation - morphological and functional - will allow better definition of radiological evaluation of the therapeutic effect of angiogenesis inhibitors on brain metastasis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Brain metastasis remain a common complication of many solid tumors, occurring from 10 to 20% of patients with cancer, and the incidence may arise up to 20-40% in autopsy series. Despite the treatment, the patient outcome is poor and brain metastasis become a major cause of death from cancer.
Some recent studies showed an increase incidence of brain metastasis; several explanations are evocated:
- The increased efficacy of brain imaging in screening of brain metastasis.
- The relative longer life expectancy of cancer patients in correlation with more efficient therapies (new chemotherapy drugs, targeted therapies) for visceral and bone metastasis, but without effect on the risk of brain metastasis (sanctuary effect),
Therapeutic management of brain metastasis: standards of care and improvement strategies
For patients with a poor survival hope, the treatment is limited to best supportive care with a palliative intent. At the opposite, a specific treatment of brain metastasis must be proposed when a real benefit may be expected.
Surgery or radiosurgery are indicated for limited brain involvement (1 to 3 metastasis).
In case of multiple localisations, whole brain radiation therapy (WBRT) is the most common approach; however this treatment is realized with a palliative intent: control of neurological symptoms and brain oedema.
In the literature, an objective response rate of 50-60 % is expected from WBRT, but the majority of these patients will relapse and died from brain metastasis, with a median survival time of 4 to 6 months.
Considering these poor results, it seems crucial to develop some innovative strategies, in order to improve the survival hope for these patients.
Different concomitant approaches were tested in association with WBRT (cytotoxics such as temozolomide, radio-sensitizers such as efaproxiral), and more recently combination of radiation therapy with therapy targeting different signalling pathway were developed, for example with lapatinib for HER2 pathway. Targeted therapies acting on neoangiogenesis seem also may be considered as an interesting axis of research.
Rationale utilisation of angiogenesis inhibitors for treatment of brain metastasis
Neo-angiogenesis plays an important role in the growth of brain metastasis, acting on different mechanisms such as tumor neo-angiogenesis (by development of new blood vessels), co-option with existing blood vessels and increased vascular permeability. Therefore, angiogenesis inhibitors, particularly agents targeting VEGF/VEGFR pathway, could be interesting in the treatment of brain metastasis.
In pre-clinical models, VEGF is the best characterized mediator of angiogenesis, and its role was pointed in the development of brain metastasis: increased transmigration of tumor cells through the blood-brain barrier by a VEGF-dependent disrupting effect, anti-apoptotic effect of VEGF by a paracrine action.
This data suggest a therapeutic effect of VEGF targeting agents on brain metastasis and a decrease of brain metastasis development has been observed in some anti-VEGF anti-sens therapy.
Moreover, VEGF involves vascular permeability and this mechanism is important in the development of peri-tumoral oedema.
Anti-angiogenic treatments are divided in two groups: on one hand, angiogenesis inhibitors (acting by normalization of the existing tumor vascularisation and through a decreased formation of new blood vessels) and on the other hand, vascular disrupting agents (which can destroy pathologic vessels).
For brain tumors, most of studies were focused on the role of angiogenesis inhibitors. Of special interest, anti-VEGF therapies, particularly the bevacizumab, were tested in clinical setting. Bevacizumab, a monoclonal recombinant antibody targeting VEGF, prevents the fixation of VEGF to VEGF receptors 1 and 2 on the endothelial cells, with a neutralizing effect on VEGF action.
In clinic, recent studies showed a significant benefit of bevacizumab (Avastin®) in the treatment of primary brain tumors, as shown by Vredenburgh et al. for patients with recurrent gliomas; these data confirm a synergic effect with chemotherapy. Similarly, a potential synergic action in a combined approach with radiation therapy seems to be an interesting therapeutic way.
Rationale for combining angiogenesis inhibitors with radiation therapy
In the tumor, the pathologic neo-angiogenesis reduces the diffusion of oxygen, and consequently promotes hypoxia. Hypoxia is one of the most causes of radio-resistance.
Ionizing radiations induce transient hypoxia in the central area of the tumor, increasing the production of VEGF and consequently the neo-angiogenesis. This "vicious circle" allows the development of optimal conditions for radio-resistance.
The normalization of pathologic vessels induced by angiogenesis inhibitors leads to a decrease of hypoxia and thus enhance the radio-sensitivity of tumor cells and endothelial cells.
In clinical setting, some studies were published about treatments combining radiation therapy and angiogenic inhibitors. The main study was conducted for rectal carcinoma (9), showing a safety profile of a combined scheme of bevacizumab and capecitabine in association with pre-operative pelvic irradiation. Efficacy data are encouraging (downstaging for 9 /11 patients, histological regression for 5 patients). Similar conclusions may be drawn from another study performed in patients with unresectable pancreatic carcinoma treated with a radio-chemotherapy including bevacizumab, leading to an objective response for 9 patients (20 %), 4 of them were operable at the end of radio-chemotherapy.
Interestingly, this combined approach seems interesting for brain tumors, as shown by a recent published trial conducted by Narayana in first-line treatment of gliomas. This phase 2 study combined temozolomide chemotherapy with bevacizumab administration for a dose of 10 m/kg at D14 and D28 during the course of radiotherapy (total dose of 59,40 Gy delivered to the tumor volume). An promising response rate was observed: 7% of complete response and 93% of partial response, the 1-year progression-free survival was 59,3%. The authors confirm the feasibility of this combined approach (13/15 patients completed their treatment). Three grade 3-4 haematological toxicities and 4 non-haematological toxicities (thrombo-embolism and HTA) are related. None intracerebral hemorrhage or death related to the treatment was reported.
These results indicate a possible way of innovative strategies in the therapeutic management of brain metastasis, by association of bevacizumab and whole brain radiation therapy. Furthermore, bevacizumab is now indicated for several advanced and/or metastatic cancer but its administration remains theorically contra-indicated for patients with brain metastasis, due to the fear of potential cerebral hemorrhage. However, this risk remains low, as shown by several studies.
Safety data were recorded with glioblastomas are reassuring, however, it is essential to determine the optimal dose level of bevacizumab when combined with irradiation of the entire brain at a dose of 30 Gy Thus for the phase 1 pilot study that we plan to carry, it is important to test several dose levels of bevacizumab in combination with irradiation of the brain: a precaution we have decided to use a conventional fractionation of 15 Gy in 2 fractions three weeks. Secondarily, given the good tolerability of this modality in combination with three levels of dose of bevacizumab used, we propose to continue the phase 1 according to the scheme commonly used in palliative situation (30 Gy in 10 fractions and 2 weeks) in combination with Avastin at a dose of 15 mg / kg, at which a maximum limiting toxicity has been observed.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Caen, France, 14076
- Centre François Baclesse
-
Lille, France, 59020
- Centre Oscar Lambret
-
Lyon, France, 69373
- Centre Léon Bérard
-
Paris, France, 75248
- Institut Curie
-
Rouen, France, 76038
- Centre Henri Becquerel
-
St Herblain, France, 44805
- Centre Rene Gauducheau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 < age < 70 man or woman
- Patient with a cytologically or histologically proven primary solid tumor
- With measurable and inoperable brain metastasis,
- Without meningeal carcinomatosis ,
- ECOG performance status ≤ 2,
- No previous treatment with angiogenesis inhibitors less than 3 months before inclusion,
- No chemotherapy and/or immunotherapy less than 3 weeks before treatment,
- No contra-indication to bevacizumab,
- No proteinuria with urine dipstick for proteinuria > 2+
- Blood sample ≤ 7 days before inclusion:
- Hemoglobin ≥ 10 G/100 ml
- Neutrophils count ≥ 1500 /mm3
- Platelets ≥ 100 000 /mm3
- Normal coagulation test: INR ≤ 1,5 ET TCA ≤ 1,5 x LSN 7 days before inclusion
- A written informed consent must be obtained.
Exclusion Criteria:
- Haemorrhagic brain metastasis,
- Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg). Patients with high initial blood pressure are eligible if entry criteria are met after initiation or adjustment of antihypertensive medication,
- Prior brain radiation therapy
- Concomitant anticoagulant treatment
- Significant surgical procedure less than 28 days before inclusion (1 day if minor surgical act)
- Significant cardio-vascular disease, eg:
- Cerebral vascular thrombosis/haemorrhage or myocardial infarction <6 months
- Congestive heart failure > 2 NYHA
- Uncontrolled coronary disease
- Prior venous and/or arterial thrombosis < 6 months before inclusion
- Severe concurrent uncontrolled medical disease,
- Any psychiatric disorder that might prevent the subject from completing the treatment or interfere with the interpretation of the study results,
- Pregnancy or breast feeding
- Individual deprived of liberty or placed under the authority of a tutor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bevacizumab
first level dose : 5 mg/kg Second level dose : 10 mg/kg Third level dose : 15 mg/kg
|
5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain. For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week. For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Maximal Tolerated dose (MTD)
Time Frame: The MTD will be evaluated 6 weeks after the first administration ob bevacizumab
|
The primary objective is to determine the Maximal Tolerated Dose (MTD) of the combination of bevacizumab and whole brain radiation therapy for patients with brain metastases
|
The MTD will be evaluated 6 weeks after the first administration ob bevacizumab
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor regression
Time Frame: The first evaluation will be performed 2 weeks after the first injection, 6 weeks after the end of radiotherapy and each 3 months
|
The secondary objective is to assess the treatment-related parameters of tumor regression by a morphologic and functional MRI six weeks after the end of the treatment.
|
The first evaluation will be performed 2 weeks after the first injection, 6 weeks after the end of radiotherapy and each 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christelle LEVY, MD, Centre François Baclesse
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Site
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms
- Neoplasm Metastasis
- Brain Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- REBECA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Malignant Neoplasm to Brain
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedMalignant Neoplasm | Metastatic Malignant Neoplasm to the BoneUnited States
-
Chuangzhen ChenRecruitingRadiotherapy | Immune Checkpoint Blockade | Metastatic Extracranial Malignant Solid Neoplasm | Resistance to ImmunotherapyChina
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the BrainUnited States
-
Sameek RoychowdhuryNational Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ALK Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Advanced Malignant Neoplasm | ALK Fusion Protein Expression | Metastatic Malignant Neoplasm in the Central Nervous System | ROS1 Gene Mutation | ALK Gene... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Metastatic Malignant Neoplasm in the BrainUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm | Metastatic Malignant Neoplasm in the BrainUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
M.D. Anderson Cancer CenterTerminatedLeukemia | Metastatic Malignant Neoplasm to the Leptomeninges | Lymphoid MalignanciesUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Advanced Malignant NeoplasmUnited States
Clinical Trials on Bevacizumab
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingStage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small... and other conditionsUnited States